US 2013/0095060 A1Published application

Pharmaceutical composition for promoting arteriogenesis, and preparation method and applications for the same

AssigneeNational Cheng Kung University

InventorsPATRICK C.H. HSIEH, YI-DONG LIN

Life of this patent

Estimating the term…

Abstract

The present invention relates to a pharmaceutical composition for promoting arteriogenesis, and preparation method and applications of the same, wherein said pharmaceutical composition comprises an effective amount of a drug, and a peptide hydrogel, and it forms a microenvironment for autologous cell recruitment and tissue regeneration.

Claims21

Dependent claims

A pharmaceutical composition for promoting arteriogenesis, comprising:

(1) an effective amount of a drug for promoting arteriogenesis selected from the group consisting of vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), granulocyte colony-stimulating factor (GCSF), granulocyte-macrophage colony stimulating factor (GM-CSF), hepatocyte growth factor (HGF), angiopoietin, epidermal growth factor (EGF), nerve growth factor (NGF), transforming growth factor (TGF), platelet-derivated growth factor (PDGF), insulin-like growth factor (IGF), brain-derived neurotrophic factor (BDNF), keratinocyte growth factor (KGF), bone morphogenetic protein (BMP), erythropoietin (EPO) and placental growth factor (PIGF);
and
(2) a peptide hydrogel comprising a self-assembling peptide selected from the group consisting of the following sequences:
(SEQ ID NO:
1)
AcN-AKAKAEAEAKAKAEAE-NH2;
(SEQ ID NO:
2)
AcN-AKAEAKAEAKAEAKAE-NH2;
(SEQ ID NO:
3)
AcN-EAKAEAKAEAKAEAKA-NH2;
(SEQ ID NO:
4)
AcN-KAEAKAEAKAEAKAEA-NH2;
(SEQ ID NO:
5)
AcN-AEAKAEAKAEAKAEAK-NH2;
(SEQ ID NO:
6)
AcN-ADADARARADADARAR-NH2;
(SEQ ID NO:
7)
AcN-ARADARADARADARAD-NH2;
(SEQ ID NO:
8)
AcN-DARADARADARADARA-NH2;
(SEQ ID NO:
9)
AcN-RADARADARADARADA-NH2;
(SEQ ID NO:
10)
AcN-ADARADARADARADAR-NH2;
(SEQ ID NO:
11)
AcN-ARADAKAEARADAKAE-NH2;
(SEQ ID NO:
12)
AcN-AKAEARADAKAEARAD-NH2;
(SEQ ID NO:
13)
AcN-ARAKADAEARAKADAE-NH2;
(SEQ ID NO:
14)
AcN-AKARAEADAKARADAE-NH2;
(SEQ ID NO:
15)
AcN-AQAQAQAQAQAQAQAQ-NH2;
(SEQ ID NO:
16)
AcN-VQVQVQVQVQVQVQVQ-NH2;
(SEQ ID NO:
17)
AcN-YQYQYQYQYQYQYQYQ-NH2;
(SEQ ID NO:
18)
AcN-HQHQHQHQHQHQHQHQ-NH2;
(SEQ ID NO:
19)
AcN-ANANANANANANANAN-NH2;
(SEQ ID NO:
20)
AcN-VNVNVNVNVNVNVNVN-NH2;
(SEQ ID NO:
21)
AcN-YNYNYNYNYNYNYNYN-NH2;
(SEQ ID NO:
22)
AcN-HNHNHNHNHNHNHNHN-NH2;
(SEQ ID NO:
23)
AcN-ANAQANAQANAQANAQ-NH2;
(SEQ ID NO:
24)
AcN-AQANAQANAQANAQAN-NH2;
(SEQ ID NO:
25)
AcN-VNVQVNVQVNVQVNVQ-NH2;
(SEQ ID NO:
26)
AcN-VQVNVQVNVQVNVQVN-NH2;
(SEQ ID NO:
27)
AcN-YNYQYNYQYNYQYNYQ-NH2;
(SEQ ID NO:
28)
AcN-YQYNYQYNYQYNYQYN-NH2;
(SEQ ID NO:
29)
AcN-HNHQHNHQHNHQHNHQ-NH2;
(SEQ ID NO:
30)
AcN-HQHNHQHNHQHNHQHN-NH2;
(SEQ ID NO:
31)
AcN-AKAQADAKAQADAKAQAD-NH2;
(SEQ ID NO:
32)
AcN-VKVQVDVKVQVDVKVQVD-NH2;
(SEQ ID NO:
33)
AcN-YKYQYDYKYQYDYKYQYD-NH2;
(SEQ ID NO:
34)
AcN-HKHQHDHKHQHDHKHQHD-NH2;
(SEQ ID NO:
35)
AcN-RARADADARARADADA-NH2;
(SEQ ID NO:
36)
AcN-RADARGDARADARGDA-NH2;
(SEQ ID NO:
37)
AcN-RAEARAEARAEARAEA-NH2;
(SEQ ID NO:
38)
AcN-KADAKADAKADAKADA-NH2;
(SEQ ID NO:
39)
AcN-AEAEAHAHAEAEAHAH-NH2;
(SEQ ID NO:
40)
AcN-FEFEFKFKFEFEFKFK-NH2;
(SEQ ID NO:
41)
AcN-LELELKLKLELELKLK-NH2;
(SEQ ID NO:
42)
AcN-AEAEAKAKAEAEAKAK-NH2;
(SEQ ID NO:
43)
AcN-AEAEAEAEAKAK-NH2;
(SEQ ID NO:
44)
AcN-KAKAKAKAEAEAEAEA-NH2;
(SEQ ID NO:
45)
AcN-AEAEAEAEAKAKAKAK-NH2;
(SEQ ID NO:
46)
AcN-RARARARADADADADA-NH2;
(SEQ ID NO:
47)
AcN-ADADADADARARARAR-NH2;
(SEQ ID NO:
48)
AcN-DADADADARARARARA-NH2;
(SEQ ID NO:
49)
AcN-HEHEHKHKHEHEHKHK-NH2;
(SEQ ID NO:
50)
AcN-VEVEVEVEVEVEVEVEVEVE-NH2;
and
(SEQ ID NO:
51)
AcN-RFRFRFRFRFRFRFRFRFRF-NH2;
in which the right end of said sequences is not —CNH2, and the pharmaceutical composition forms a microenvironment for autologous cell recruitment and tissue regeneration.

155 more elements

Dependencies are inferred from the claim text.

patentgrep

Loading patent…

Abstract

A pharmaceutical composition for promoting arteriogenesis, comprising:

(1) an effective amount of a drug for promoting arteriogenesis selected from the group consisting of vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), granulocyte colony-stimulating factor (GCSF), granulocyte-macrophage colony stimulating factor (GM-CSF), hepatocyte growth factor (HGF), angiopoietin, epidermal growth factor (EGF), nerve growth factor (NGF), transforming growth factor (TGF), platelet-derivated growth factor (PDGF), insulin-like growth factor (IGF), brain-derived neurotrophic factor (BDNF), keratinocyte growth factor (KGF), bone morphogenetic protein (BMP), erythropoietin (EPO) and placental growth factor (PIGF);
and
(2) a peptide hydrogel comprising a self-assembling peptide selected from the group consisting of the following sequences:
(SEQ ID NO:
1)
AcN-AKAKAEAEAKAKAEAE-NH2;
(SEQ ID NO:
2)
AcN-AKAEAKAEAKAEAKAE-NH2;
(SEQ ID NO:
3)
AcN-EAKAEAKAEAKAEAKA-NH2;
(SEQ ID NO:
4)
AcN-KAEAKAEAKAEAKAEA-NH2;
(SEQ ID NO:
5)
AcN-AEAKAEAKAEAKAEAK-NH2;
(SEQ ID NO:
6)
AcN-ADADARARADADARAR-NH2;
(SEQ ID NO:
7)
AcN-ARADARADARADARAD-NH2;
(SEQ ID NO:
8)
AcN-DARADARADARADARA-NH2;
(SEQ ID NO:
9)
AcN-RADARADARADARADA-NH2;
(SEQ ID NO:
10)
AcN-ADARADARADARADAR-NH2;
(SEQ ID NO:
11)
AcN-ARADAKAEARADAKAE-NH2;
(SEQ ID NO:
12)
AcN-AKAEARADAKAEARAD-NH2;
(SEQ ID NO:
13)
AcN-ARAKADAEARAKADAE-NH2;
(SEQ ID NO:
14)
AcN-AKARAEADAKARADAE-NH2;
(SEQ ID NO:
15)
AcN-AQAQAQAQAQAQAQAQ-NH2;
(SEQ ID NO:
16)
AcN-VQVQVQVQVQVQVQVQ-NH2;
(SEQ ID NO:
17)
AcN-YQYQYQYQYQYQYQYQ-NH2;
(SEQ ID NO:
18)
AcN-HQHQHQHQHQHQHQHQ-NH2;
(SEQ ID NO:
19)
AcN-ANANANANANANANAN-NH2;
(SEQ ID NO:
20)
AcN-VNVNVNVNVNVNVNVN-NH2;
(SEQ ID NO:
21)
AcN-YNYNYNYNYNYNYNYN-NH2;
(SEQ ID NO:
22)
AcN-HNHNHNHNHNHNHNHN-NH2;
(SEQ ID NO:
23)
AcN-ANAQANAQANAQANAQ-NH2;
(SEQ ID NO:
24)
AcN-AQANAQANAQANAQAN-NH2;
(SEQ ID NO:
25)
AcN-VNVQVNVQVNVQVNVQ-NH2;
(SEQ ID NO:
26)
AcN-VQVNVQVNVQVNVQVN-NH2;
(SEQ ID NO:
27)
AcN-YNYQYNYQYNYQYNYQ-NH2;
(SEQ ID NO:
28)
AcN-YQYNYQYNYQYNYQYN-NH2;
(SEQ ID NO:
29)
AcN-HNHQHNHQHNHQHNHQ-NH2;
(SEQ ID NO:
30)
AcN-HQHNHQHNHQHNHQHN-NH2;
(SEQ ID NO:
31)
AcN-AKAQADAKAQADAKAQAD-NH2;
(SEQ ID NO:
32)
AcN-VKVQVDVKVQVDVKVQVD-NH2;
(SEQ ID NO:
33)
AcN-YKYQYDYKYQYDYKYQYD-NH2;
(SEQ ID NO:
34)
AcN-HKHQHDHKHQHDHKHQHD-NH2;
(SEQ ID NO:
35)
AcN-RARADADARARADADA-NH2;
(SEQ ID NO:
36)
AcN-RADARGDARADARGDA-NH2;
(SEQ ID NO:
37)
AcN-RAEARAEARAEARAEA-NH2;
(SEQ ID NO:
38)
AcN-KADAKADAKADAKADA-NH2;
(SEQ ID NO:
39)
AcN-AEAEAHAHAEAEAHAH-NH2;
(SEQ ID NO:
40)
AcN-FEFEFKFKFEFEFKFK-NH2;
(SEQ ID NO:
41)
AcN-LELELKLKLELELKLK-NH2;
(SEQ ID NO:
42)
AcN-AEAEAKAKAEAEAKAK-NH2;
(SEQ ID NO:
43)
AcN-AEAEAEAEAKAK-NH2;
(SEQ ID NO:
44)
AcN-KAKAKAKAEAEAEAEA-NH2;
(SEQ ID NO:
45)
AcN-AEAEAEAEAKAKAKAK-NH2;
(SEQ ID NO:
46)
AcN-RARARARADADADADA-NH2;
(SEQ ID NO:
47)
AcN-ADADADADARARARAR-NH2;
(SEQ ID NO:
48)
AcN-DADADADARARARARA-NH2;
(SEQ ID NO:
49)
AcN-HEHEHKHKHEHEHKHK-NH2;
(SEQ ID NO:
50)
AcN-VEVEVEVEVEVEVEVEVEVE-NH2;
and
(SEQ ID NO:
51)
AcN-RFRFRFRFRFRFRFRFRFRF-NH2;
in which the right end of said sequences is not —CNH2, and the pharmaceutical composition forms a microenvironment for autologous cell recruitment and tissue regeneration.

155 more elements